314 Results (Page 4 of 13)
Australia Markets Research Reports
Australia Palliative Care Market Analysis
Australia's palliative care market is projected to grow from $156.96 Mn in 2022 to $324.42 Mn by 2030, registering a CAGR of 9.5% during the forecast period of 2022–30. The main factors driving the growth would be as increasing prevalence of chronic diseases, the growing aging population, advancements in technology, and government support. The market is segmented by service type and by the end user. Some of the major players include Hammond Care, Japara Healthcare, Aveo Group, Brightwater Care Group, and Home Instead.
Australia ENT Devices Market Analysis
Australia's ENT Devices Market is projected to grow from $280 Mn in 2022 to $490 Mn by 2030, registering a CAGR of 7% during the forecast period of 2022-30. The rising prevalence of ENT disorders, such as hearing loss, sinusitis, and tonsillitis, is a major driver of the ENT device market. The market is highly competitive, with a large number of players operating in the space, ranging from small, specialized companies to large multinational corporations. The domestic key players in the Australian ENT devices market include CoreMed ENT, Zonemedical, and Teleflex Medical Australia.
Australia Digital Health Market Analysis
Australia's digital health market was valued at $2.5 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 20.10% from 2022 to 2030 and will reach $10.96 Bn in 2030. One of the main reasons propelling the growth of this market is rising smartphone adoption, improved internet connectivity, and improved healthcare. The market is segmented by product, by end-user, and by component. Some key players in this market are Alcidion Corp., Doctors on Demand Pty Ltd, Ellume Limited, Genie Solutions Pty Ltd, and Harrison-Al Pty Ltd.
Australia Diabetes Therapeutics Market Analysis
Australia's diabetes therapeutics market is expected to grow from $1.72 Bn in 2022 to $4.03 Bn in 2030 with a CAGR of 11.2% for the forecasted year 2022-30. Various government initiatives such as the National Diabetes Services Scheme, the Pharmaceutical Benefits Scheme, the Insulin Pump Program, and Medicare provide diabetes assistance to Australian citizens, a significant factor driving the market's growth. The Australian diabetes therapeutics market is segmented by type, application, drug, route of administration, and distribution channel. MycRx, Cynapse Bio, and Novartis are the major players in the Australian diabetes therapeutics market.
Australia Coronary Stents Market Analysis
Australia's Coronary Stents Market is expected to witness growth from $136 Mn in 2022 to $220 Mn in 2030 with a CAGR of 6.25% for the forecasted year 2022-30. In Australia, the coronary stent market is expanding as a result of the growing use of stenting treatments among medical professionals, such as cardiologists and interventional radiologists. The market is segmented by type, mode of delivery, materials, and end user. Some key players in this market include Endoluminal Sciences, Austramedex, B. Braun, Abbott Laboratories, Biotronik, Medtronic, GE Healthcare, Boston Scientific, and Philips Healthcare.
Australia Contraceptive Devices Market Analysis
Australia's Contraceptive Devices Market is expected to witness growth from $155 Mn in 2022 to $320 Mn in 2030 with a CAGR of 9.50% for the forecasted year 2022-30. Australian women are becoming more aware of the value of family planning and contraception. As a result, there is now a higher need for contraceptive methods. The market is segmented by type and by gender. Some key players in this market include Ansell, Lifestyles Healthcare, Mylan Laboratories, Mankind Pharma, CooperSurgical, Pfizer, Pregna International, and Teva Pharmaceutical.
Australia Connected Healthcare Market Analysis
The Australia-connected healthcare market is projected to grow from $796.32 Mn in 2022 to $6444.96 Mn by 2030, registering a CAGR of 29.9% during the forecast period of 2022-30. The main factors driving the growth would be the rising geriatric population, geographic challenges, technological innovation, and government investment. The market is segmented by type, function, and application. Some of the major players include Telstra Health, HealthEngine, ResApp, MyHealth1st, Apple, IBM and Microsoft.
Australia Biomaterials in Healthcare Market Analysis
Australia Biomaterials Healthcare Market is expected to witness growth from $1.87 Bn in 2022 to $5.61 Bn in 2030 with a CAGR of 14.70% for the forecasted year 2022-30. The demand for biomaterials in Australia is being driven by the rising prevalence of diseases like periodontal disease, tooth decay, oral cancer, halitosis, and dental caries, which is anticipated to spur development in the country's biomaterial healthcare market. The market is segmented by type and by application. Some key players in this market include Anatomics, PolyNovo, OPED Australia, BASF SE, Johnson and Johnson, Medtronic, and Evonik Industries.
Australia Antifungal Drugs Market Analysis
This report presents a strategic analysis of the Australian antifungal Drugs Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the Australian Antifungal Drugs Market, offering unmatched value, accuracy, and expert insights.
Australia Over The Counter (OTC) Pharmaceuticals Market Analysis
Australia's over-the-counter (OTC) pharmaceuticals market size was valued at $1650 Mn in 2022 and is estimated to expand at a CAGR of 7.04% from 2022 to 2030 and will reach $2843.5 Mn in 2030. OTC are non-prescription medications and are a vital component of the healthcare system, offering consumers accessible solutions for a wide range of common health issues. The market is segmented by product type and distribution channel. The key market players are Johnson and Johnson Services Inc (USA), Bayer AG (Germany), Novartis AG (Switzerland) and others.
Australia Diabetes Devices Market Analysis
Australian Diabetes Devices Market is expected to witness growth from $273 Mn in 2022 to $532 Mn in 2030 with a CAGR of 8.70% for the forecasted year 2022-30. In Australia, the market for diabetes devices is expanding as a result of the rise in the number of people with the condition and the demand for diabetes devices that can assist people in managing their condition. The market is segmented by type and by the end user. Some key players in this market include Fairmont Medical Products, Cook Medical Australia, Johnson & Johnson, Medtronic, Roche, Ascensia diabetes care, and Dexcom.
Australia Cancer Immunotherapy Market Analysis
Australia's cancer immunotherapy market is expected to grow from $1.35 Bn in 2022 to $2.61 Bn in 2030 with a CAGR of 8.6% for the forecasted year 2022-30. The rising incidence of cancer cases and supportive government programs to promote cancer immunotherapy in Australia are responsible for the growth of the market. The Australian cancer immunotherapy market is segmented by type, application, and end user. Bioarc, Pharmaxis, and Bristol-Myers Squibb are the major players in the Australian cancer immunotherapy market.
Australia Anemia Drugs Market Analysis
Australia's Anemia drugs market was valued at $192 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 10.4% from 2022 to 2030 and will reach $423 Mn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, and awareness among people in Australia. The market is segmented by type, drug, and distribution channel. Some key players in this market are Pfizer, Roche, Sanofi, Novartis, Merck, Novo Nordisk, Otsuka, and Baxter among others.
Australia Oral Care Market Analysis
Australia's oral care market was valued at $423 Mn in 2022 and is estimated to expand at a CAGR of 7.7% from 2022 to 2030 and will reach $765 Mn in 2030. One of the main reasons propelling the growth of this market is increasing disposable income and the aging population. The market is segmented by type, drug, and distribution channel. Some key players in this market are White Glo, Grants of Australia, Red Seal, Dr. Brite, and Pure Smile
Australia Alzheimer’s Disease Drug Market Analysis
Australia's alzheimer’s disease drug market is expected to grow from $174.09K in 2022 to $222.94K in 2030 with a CAGR of 2.8% for the year 2022-30. Rising Alzheimer’s cases in Australia and increased investments by the government in the development of diagnostics and treatment modalities for Alzheimer’s disease in Australia are major market drivers of the Australia alzheimer’s disease drug market. The market is segmented by product, by drugs, and by distribution channel. Xenexus Pharmaceutical, Mediland Pharm, and Merz Pharma are some of the key players in this market.
Australia Sickle Cell Disease Drug Market Analysis
Australia's Sickle Cell Disease Drug Market is expected to grow from $1.1 Mn in 2022 to $2.6 Mn in 2030 with a CAGR of 11% for the year 2022-2030. Immigration from other countries such as Africa and the Middle East etc along with newly licensed drugs for the treatment of sickle cell disease is driving the growth of the Australia Sickle Cell Disease Drug Market. the market is segmented by treatment modalities and by distribution channel. Some of the key players in the Australia Sickle Cell Disease Drug Market are Baxter Healthcare, Lipa Pharmaceutical, and Pfizer.
Australia Multiple Sclerosis Drugs Market Analysis
Australia Multiple Sclerosis Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for Multiple sclerosis is rising due to increase in Incidence and prevalence of multiple sclerosis (MS), Improved diagnosis and awareness, advancements in healthcare infrastructure , Advancements in Treatment Options, Expanding Pipeline of Innovative Therapies, technological advancements and increase in funding for research of multiple sclerosis. Major global players in Multiple Sclerosis Drugs Market are Abbott (U.S.), Bristol-Myers Squibb Company (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Takeda Pharmaceutical Company Limited (Japan), Jazz Pharmaceuticals, Inc. (U.K.), Novartis AG (Switzerland), Biora Therapeutics, Inc. (U.S.), Bausch Health Companies Inc. (Canada), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Mylan N.V. (U.S.)
Australia Myasthenia Gravis Drugs Market Analysis
Australia Myasthenia Gravis Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for myasthenia gravis is rising due to increasing prevalence and incidence of disease, improved diagnostic techniques, increased awareness and better understanding of the disease, Supportive Government Initiatives like providing financial support, improving healthcare infrastructure, promoting research in rare diseases and Technological Advancements in drugs and therapies treating myasthenia gravis. Major global players in Myasthenia Gravis Drugs Market are Alexion Pharmaceuticals, Inc., Bausch Health Companies, Inc., Novartis AG, Amneal Pharmaceuticals LLC, Zydus Cadila, Avadel, Dr. Reddy's Laboratories, Ltd., Fresenius Kabi, AG, Endo Pharmaceuticals, Inc., Amphastar Pharmaceuticals, Inc., Mylan N.V., Aurobindo Pharma, Pfizer, Inc., Astellas Pharma, Inc.
Australia POMC Genetic Obesity Drugs Market Analysis
Australia POMC Genetic Obesity Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for POMC Genetic Obesity Drugs is growing due to increase spending in research and development activities by pharmaceutical companies, introduction of new emerging therapies like gene editing and gene replacement approaches, incentives provided by regulatory body?s in the form of orphan drug designations. Novo Nordisk A/S , rhythm Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated ,Amgen Inc are the key market players operating in global POMC genetic obesity drugs market.
Australia Pompe Disease Drugs Market Analysis
Australia Pompe Disease Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Pompe disease Drugs is growing due to increase in awareness about the disease , better diagnosis, advancements in treatment options and increase in research and development activities by different pharmaceutical companies and research organizations. Sanofi Genzyme ,BioMarin Pharmaceutical Inc., Avrobio Inc., Amicus Therapeutics Inc. are the key market players operating in global pompe disease market.
Australia Rare Hematology Disorders Market Analysis
Australia Rare Hematology Disorders market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Rare Hematology Disorders is growing rapidly as a result of increase in incidence of rare blood disorders, increase in awareness of rare hematology disorders, advancement in genetic testing and diagnostic techniques, increase in spending on healthcare infrastructure and increasing adoption of gene therapy. Sanofi Genzyme, Pfizer Inc., Novartis AG, Alexion Pharmaceuticals, Shire., BioMarin Pharmaceutical Inc., CSL Behring are the key global market players operating in rare hematology disorders market.
Australia Rare Hemophilia Factors Market Analysis
Australia Rare Hemophilia Factors market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Rare Hemophilia Factors is growing rapidly as a result of growing incidence of rare hemophilia factors deficiency, rising adoption of prophylactic treatments, growing awareness about rare hemophilia factors and their treatment options, rising demand for better and more effective therapies for rare hemophilia factors. Baxter, Bayer AG, Bio Products Laboratory Ltd., Novo Nordisk A/S, Alexion Pharmaceuticals, Amgen Inc, BioMarin, Amgen Inc are the key global market players operating in rare hemophilia factors market.
Australia Rett Syndrome Drugs Market Analysis
Australia Rett Syndrome Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for Rett syndrome will grow over time as a result of expanding female population, rising public healthcare programme spending for patient advocacy and rising global healthcare expenditure. Major global players in Rett Syndrome Drugs Market are Merck KGaA (Germany), Eisai Co., Ltd. (Japan), AstraZeneca (U.K.), Sanofi (France), Novartis AG (Switzerland), Abbott (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Teva Pharmaceutical Industries Ltd. (Ireland), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), WOCKHARDT (Mumbai), Novo Nordisk A/S (Denmark), Glenmark Pharmaceuticals Limited (India), Cipla Inc. (U.S.), Bausch Health Companies Inc. (Canada), Otsuka America Pharmaceutical, Inc. (U.S.), Johnson & Johnson Private Limited (U.S.), Takeda Pharmaceutical Company Limited (Japan), Sumitomo Corporation (Japan), Biocon (India)
Australia Sickle Cell Disease Drugs Market Analysis
Australia Sickle cell disease Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Sickle cell disease Drugs is growing rapidly as a result of increasing prevalence of sickle cell disease , increasing investment for healthcare infrastructure, increase in the number of research and development activities, Support provided by governments of different countries, patient advocacy programmes and incentives provided by regulatory authorities. Global Blood Therapeutics, Novartis, Emmaus Life Sciences, Bluebird Bio, Teva Pharmaceutical Industries Ltd, Pfizer Inc., Mylan N.V., Merck & Co., Inc., Johnson & Johnson Private Limited, Bristol-Myers Squibb Company, AbbVie Inc are the key global market players operating in sickle cell disease Drugs market.
Australia Soft Tissue Sarcoma Market Analysis
Australia Soft Tissue Sarcoma market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Soft Tissue Sarcoma is growing rapidly as a result of increasing prevalence and incidence of soft tissue sarcoma, rising awareness about the disease, rising research and development activities on drugs and other therapies, increase in partnerships between pharmaceutical companies for drug development and advancements in diagnostics. Pfizer Inc, Eli Lilly and Company, Johnson & Johnson, Bayer AG, Eisai Co., Ltd., Epizyme, Inc., Adaptimmune Therapeutics, Mylan N.V., Sanofi are the key market players operating in global Soft Tissue Sarcoma market.